继发性甲状旁腺功能亢进（ SHPT）是慢性肾脏病的重要并发症，是慢性肾脏病及其所致的血磷、血钙和活性维生素D代谢紊乱的代偿性反应。SHPT可增加软组织和血管钙化的风险，是心血管事件与死亡的重要预测因子，严重影响患者的生活质量和生存率。目前的治疗药物主要包括磷结合剂、维生素 D 及其类似物、钙敏感受体（ CaSR）激动剂。近年来，许多新药应用于临床取得了良好的效果，包括新型磷结合剂（司维拉姆和碳酸镧）、活性维生素D类似物（帕立骨化醇和度骨化醇）、CaSR激动剂（西那卡塞）等，本文将SHPT药物治疗进展情况进行综述。%Secondary hyperparathyroidism ( SHPT ) is one of the most important complications of chronic kidney disease( CKD),and it is the compensatory reaction of phosphorus,calcium and active vitamin D metabolism disorder. SHPT, a predictor of cardiovascular events and death,may lead to the calcification of soft tissue and angiosteosis and seriously influence the quality of life and survival rate of patients. The main drugs for SHPT are phosphate binder,vitamin D and its analogs and calcium sensing receptor agonist( CaSR). Recently,some new drugs for SHPT including new phosphate binder( sevelamer and lanthanum carbonate),vitamin D analogs(paricalcitol and doxercalciferol)and calcium sensing receptor agonist(cinacalcet) have obtained good effects. We made a review of the progress of drug therapy for SHPT in this paper.
展开▼
